Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 1.00 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28274320 | 0.98 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Methyl Alcohol SCHEMBL9715289 | 0.96 | FDPS (0.93) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL28381527 | 0.87 | FDPS (0.76) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL28380721 | 0.85 | FDPS (0.73) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL3659339 | 0.83 | FDPS (0.71) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL9460027 | 0.80 | FDPS (0.65) | FDPSGGPS1BTN3A1CA12CA2 | |
| Phosphonic Acid SCHEMBL10410285 | 0.78 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL8714524 | 0.78 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL5702824 | 0.78 | FDPS (0.63) | FDPSGGPS1BTN3A1CA12CA2 | |
| SCHEMBL9114540 | 0.76 | FDPS (0.61) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | claimed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | claimed |
| WO-2016081281-A1 | LIPOPHILIC BISPHOSPHONATES AND METHODS OF USE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016081281-A1 | LIPOPHILIC BISPHOSPHONATES AND METHODS OF USE | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-05-26 | — | — | WO | disclosed |
| US-20130138221-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMPLANT OSSEOINTEGRATION | NOVARTIS AG (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130082217-A1 | METHOD OF PRODUCING METAL PARTICLES, AND INK COMPOSITION AND PASTE COMPOSITION PRODUCED BY THE SAME | SAMSUNG ELECTRO-MECHANICS CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| US-20130082217-A1 | METHOD OF PRODUCING METAL PARTICLES, AND INK COMPOSITION AND PASTE COMPOSITION PRODUCED BY THE SAME | SAMSUNG ELECTRO-MECHANICS CO., LTD. (KR) | 2013-04-04 | — | — | US | disclosed |
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | GLAUSCH ALEXANDRA (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8052987-B2 | Intermittently administering a bisphosphonate to patient, wherein period between administrations of bisphosphonate is at least 6 months; treatment of osteoporosis | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2011-11-08 | — | — | US | disclosed |
| US-7932241-B2 | Filling plastic container with bisphosphonate solution; heat sterilization | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20050119230-A1 | Pharmaceutical products comprising bisphosphonated | GLAUSCH ALEXANDRA (DE) | 2005-06-02 | — | — | US | disclosed |
| US-20050014726-A1 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | NOVARTIS AG (CH) | 2005-01-20 | — | — | US | disclosed |
| US-20040157799-A1 | Pharmaceutical uses of bisphosphonates | SEAMAN JOHN J (US) | 2004-08-12 | — | — | US | disclosed |
| WO-2004035061-A1 | METHOD OF ADMINISTERING BISPHOSPHONATES | NOVARTIS AG (CH) | 2004-04-29 | — | — | WO | disclosed |
| US-20040063670-A1 | Use of bisphosphonates for pain treatment | FOX ALYSON (GB) | 2004-04-01 | — | — | US | disclosed |
| US-20030181421-A1 | Method of administering bisphosphonates | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-09-25 | — | — | US | disclosed |
| EP-0275821-B1 | SUBSTITUTED ALKANEDIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1992-02-26 | — | — | EP | disclosed |
| US-4939130-A | Substituted alkanediphosphonic acids and pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0275821-A1 | Substituted alkanediphosphonic acids | CIBA-GEIGY AG (CH) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063670-A1 | Use of bisphosphonates for pain treatment | SOST, OPRL1, BPGM | FDPS 465/4885GGPS1 261/4885BTN3A1 484/4885 |
| US-20120027818-A1 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER | PGD, RICTOR, PAICS | FDPS 90/4885GGPS1 8/4885BTN3A1 3308/4885 |
| US-20030181421-A1 | Method of administering bisphosphonates | PTH1R, SOST, BPGM | FDPS 620/4885GGPS1 224/4885BTN3A1 491/4885 |
| US-20050014726-A1 | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | PTGER2, SOST, PTGS2 | FDPS 2126/4885GGPS1 533/4885BTN3A1 4167/4885 |
| US-20050119230-A1 | Pharmaceutical products comprising bisphosphonated | BPGM, P2RY6, PIK3CA | FDPS 270/4885GGPS1 113/4885BTN3A1 4332/4885 |
| US-20100047306-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPHOSPONATES | PTEN, PPIP5K2, ACP3 | FDPS 324/4885GGPS1 236/4885BTN3A1 1226/4885 |
| US-20040157799-A1 | Pharmaceutical uses of bisphosphonates | ACP3, SOST, BPGM | FDPS 529/4885GGPS1 240/4885BTN3A1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.